About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Liver Disease Clinical Trials | 200 Studies Recruiting

Clinical TrialsLiver Disease

Liver Disease Clinical Trials

Browse 200 clinical trials for liver disease. Find studies that match your criteria and connect with research centers.

Find trials near:

New York Los Angeles Chicago Houston Phoenix Philadelphia

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 61-80 of 200 trials

CompletedChronic Kidney Disease and Non-alcoholic Fatty Liver DiseasesNon-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide.NCT04779905·Sohag RecruitingA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASHThe study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH…NCT06419374·Birmingham, Alabama and 325 others

Related Searches

cirrhosistrials nafldtrials

Data from ClinicalTrials.govTerms

CompletedBariatric Surgery and Fatty Liver DiseaseThe study is based on data from morbidly obese patients who fulfilled the criteria for bariatric surgery during 2016-2018 at the Department of Surgery, University Hospital…NCT04569396·Ostrava, Moravian-Silesian Region

CompletedStudy of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)The goal of this clinical study is to understand whether the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), cause…NCT04971785·Birmingham, Alabama and 241 others

Active not recruitingEffects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B PatientsChronic hepatitis B (CHB) affects 257million individuals worldwide. In 2017, it caused around 39.7 million cases of cirrhosis and 0.4 million cirrhosis-related deaths in 2017.NCT05147090·Hong Kong, Hong Kong, China

CompletedSafety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase DeficiencyThis was an open-label, repeat-dose, intra-participant dose-escalation study of SBC-102 (sebelipase alfa) in children with growth failure due to lysosomal acid lipase (LAL)…NCT01371825·Irvine, California and 6 others

Not yet recruitingTHE FRENCH NATIONAL NAFLD COHORT (FRench pAtients With MEtabolic Steatosis)The main objective of this cohort study is to determine genetic, clinical biologic and metabolic factors associated with patient heterogeneity in regards to severity of NAFLD at…NCT04925362

CompletedA Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASHThis is a multicenter, Phase IIb, randomized, double blind, placebo-controlled study designed to evaluate the efficacy and safety of two Aramchol doses in subjects that are 18 to…NCT02279524·Chula Vista, California and 77 others

CompletedA Study of Experimental Medication BMS-986036 Given to Healthy ParticipantsThis is a study of experimental medication BMS-986036 given to healthy participants.NCT03445208·Salt Lake City, Utah

Active not recruitingDIAbetes and NAFLDNon-alcoholic hepatic steatosis (NAFLD) is characterised by the excessive accumulation of triglycerides in the liver and is often associated, in the absence of significant alcohol…NCT06315361·Roma, Rome/lazio/italy

UnknownEffectiveness of Ultrasound in Liver Stiffness and Fat QuantificationLiver stiffness is a marker for scarring of the liver, which occurs after damage from various liver conditions.NCT06111859·London

CompletedComparative Efficacy of Liver Fibrosis and Steatosis Assessment With Fibroscan and iLivTouchThis study is aimed to compare the results and operating characteristics of liver stiffness measurement with the use of Fibroscan (EchoSens, France) and iLivTouch (Wuxi Hisky…NCT05224037·Moscow

TerminatedPalliative Care for Non-Malignant Diseases (COMPASS Trial)The purpose of this study is to evaluate, through a randomized controlled trial, the impact of integrated comprehensive palliative care services on time to first hospital…NCT03022630·Nashville, Tennessee

TerminatedStudy to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver FibrosisThis is a Phase 2, randomized, double-blind, placebo-controlled, multicenter, multinational, dose-finding study evaluating the efficacy of three treatment doses of CC-90001…NCT04048876·Phoenix, Arizona and 141 others

UnknownBariatric Endoscopy and NAFLDFind out how bariatric endoscopy will influence the clinical course of non-alcoholic fatty liver disease.NCT04895943·Ostrava, Moravian-Silesian Region

CompletedPathophysiological Implications of the Incretin Hormones in Patients With Liver Disease With and Without DiabetesThe main objective of this study is to analyze the pathophysiological implications of glucagon and the incretin hormones in patients with liver disease (Non alcoholic fatty liver…NCT01492283·Hellerup

CompletedDasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver DiseaseTo examine the effect of dasatinib plus quercetin on liver fibrosis in individuals with biopsy proven NAFLD with fibrosis by performing a double-blind randomized controlled…NCT05506488·Amsterdam

CompletedCombination Diagnostic Strategies in NAFLDSerial combination of biological and elastography tests is accurate to diagnosing advanced fibrosis in non-alcoholic fatty liver disease (NAFLD) patients.NCT04384159

CompletedA Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease PatientsA double-blind placebo controlled randomized Phase 3 study to evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching…NCT04197479·Birmingham, Alabama and 76 others

SuspendedA Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)An Open-Label Part was added: This part will enroll in selected sites which are less affected by the COVID-19 pandemic.NCT04104321·Miami, Florida and 1 other

PreviousPage 4 of 10Next